130 related articles for article (PubMed ID: 24918664)
1. Regulatory B cells present in lymph nodes draining a murine tumor.
Maglioco A; Machuca DG; Camerano G; Costa HA; Ruggiero R; Dran GI
Medicina (B Aires); 2014; 74(3):185-8. PubMed ID: 24918664
[TBL] [Abstract][Full Text] [Related]
2. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.
Wang LK; Kuang M; Hua YP; He Q; Chen B; Wang Y; Peng BG
J Surg Res; 2013 Aug; 183(2):900-6. PubMed ID: 23481561
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
Thomas SN; Vokali E; Lund AW; Hubbell JA; Swartz MA
Biomaterials; 2014 Jan; 35(2):814-24. PubMed ID: 24144906
[TBL] [Abstract][Full Text] [Related]
4. Increased B Regulatory Phenotype in Non-Metastatic Lymph Nodes of Node-Positive Breast Cancer Patients.
Mehdipour F; Razmkhah M; Hosseini A; Bagheri M; Safaei A; Talei AR; Ghaderi A
Scand J Immunol; 2016 Mar; 83(3):195-202. PubMed ID: 26708831
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
[TBL] [Abstract][Full Text] [Related]
6. TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression.
Nakamura S; Yaguchi T; Kawamura N; Kobayashi A; Sakurai T; Higuchi H; Takaishi H; Hibi T; Kawakami Y
J Immunother; 2014; 37(2):63-72. PubMed ID: 24509168
[TBL] [Abstract][Full Text] [Related]
7. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
8. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
10. Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth.
Ganti SN; Albershardt TC; Iritani BM; Ruddell A
Sci Rep; 2015 Jul; 5():12255. PubMed ID: 26193241
[TBL] [Abstract][Full Text] [Related]
11. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration.
Hultkrantz S; Ostman S; Telemo E
Immunology; 2005 Nov; 116(3):362-72. PubMed ID: 16236126
[TBL] [Abstract][Full Text] [Related]
12. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer.
Battaglia A; Buzzonetti A; Martinelli E; Fanelli M; Petrillo M; Ferrandina G; Scambia G; Fattorossi A
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1546-53. PubMed ID: 20338481
[TBL] [Abstract][Full Text] [Related]
13. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.
Lund AW; Duraes FV; Hirosue S; Raghavan VR; Nembrini C; Thomas SN; Issa A; Hugues S; Swartz MA
Cell Rep; 2012 Mar; 1(3):191-9. PubMed ID: 22832193
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients].
Su YJ; Ren K; Li H; Ren XB; Wang CL
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):922-6. PubMed ID: 18478932
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
Roberts LK
J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
[TBL] [Abstract][Full Text] [Related]
17. The balance of regulatory and stimulatory B cell subsets in breast cancer draining lymph nodes correlates with tumor prognostic factors.
Shariati S; Mehdipour F; Samadi M; Rasolmali R; Talei AR; Ghaderi A
Life Sci; 2020 Sep; 257():118117. PubMed ID: 32693243
[TBL] [Abstract][Full Text] [Related]
18. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
19. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes.
Faghih Z; Erfani N; Haghshenas MR; Safaei A; Talei AR; Ghaderi A
Immunol Lett; 2014; 158(1-2):57-65. PubMed ID: 24326038
[TBL] [Abstract][Full Text] [Related]
20. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
